Lipegfilgrastim

CHEMBL4594230 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This long-acting form of granulocyte colony-stimulating factor is given as a single injection after chemotherapy to stimulate the bone marrow to produce more white blood cells, reducing the risk of life-threatening infections. Its chemical modification extends its duration of action compared to standard filgrastim.

Aires thérapeutiques

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Hematology Pain Management Non-Small Cell Lung Cancer Oncology Lymphoma Type 2 Diabetes Breast Cancer Chronic Pain HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This long-acting form of granulocyte colony-stimulating factor is given as a single injection after chemotherapy to stimulate the bone marrow to produce more white blood cells, reducing the risk of life-threatening infections. Its chemical modification extends its duration of action compared to standard filgrastim.

Yes, Lipegfilgrastim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594230. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Lipegfilgrastim sur PillFYI

Données Clés

Liens externes

ChEMBL CHEMBL4594230

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.